Page 171 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation

Rituximab intensification during R-CHOP in DLBCL
References
1. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 346:235-242, 2002.
2. Pfreundschuh M, Schubert J, Ziepert M, et al: Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: A randomised controlled trial (RICOVER-60). Lancet Oncol. 9:105-116, 2008.
3. Delarue R, Tilly H, Mounier N, et al: Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): A randomised phase 3 trial. Lancet Oncol. 14:525-533, 2013.
4. Cunningham D, Hawkes EA, Jack A, et al: Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: A phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet. 381:1817-1826, 2013.
5. Vaidya R, Witzig TE: Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era. Ann Oncol. 25:2124-2133, 2014.
6. van Imhoff GW, McMillan A, Matasar MJ, et al: Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: The ORCHARRD study. J Clin Oncol. 35:544-551, 2017.
7. Murawski N, Pfreundschuh M, Zeynalova S, et al: Optimization of rituximab for the treatment of DLBCL (I): Dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL. Ann Oncol. 25:1800-1806, 2014.
8. Pfreundschuh M, Poeschel V, Zeynalova S, et al: Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): Extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the German high-grade non-Hodgkin lymphoma study group. J Clin Oncol. 32:4127-4133, 2014 [Erratum: J Clin Oncol 33:1991, 2015].
9. Pfreundschuh M, Müller C, Zeynalova S, et al: Suboptimal dosing of rituximab in male and female patients with DLBCL. Blood. 123:640-646, 2014.
10. Müller C, Murawski N, Wiesen MHJ, et al: The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood. 119:3276-3284, 2012.
11. Keating M, O’Brien S: High-dose rituximab therapy in chronic lymphocytic leukemia. Semin Oncol. 27:86-90, 2000 (suppl 12).
12. O’Brien SM, Kantarjian H, Thomas DA, et al: Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 19:2165-2170, 2001.
13. Pfreundschuh M, Trümper L, Kloess M, et al: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL. Blood. 104:634-641, 2004.
14. Cheson BD, Fisher RI, Barrington SF, et al: Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification. J Clin Oncol. 32:3059-3068, 2014.
15. Barrington SF, Mikhaeel NG, Kostakoglu L, et al: Role of imaging in the staging and response assessment of lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 32:3048-3058, 2014.
16. Burggraaff CN, Cornelisse AC, Hoekstra OS, et al: Interobserver agreement of interim and end- of-treatment 18F-FDG PET/CT in diffuse large B-cell lymphoma (DLBCL): Impact on clinical practice and trials. J Nucl Med. 59:1831-1836, 2018.
17. Crump M, Neelapu SS, Farooq U, et al: Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study. Blood. 130:1800-1808, 2017. [Erratum: Blood. 131:587- 588, 2018].
18. Pfreundschuh M, Murawski N, Zeynalova S, et al: Optimization of rituximab for the treatment of DLBCL: Increasing the dose for elderly male patients. Br J Haematol. 179:410-420, 2017.
169
6b